Cytomegalovirus (CMV) Clinical Trial
Official title:
A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of maribavir using a 200 milligrams (mg) adult tablet formulation or other formulation based on PK modeling. The participants will be treated with maribavir for 8 weeks. Participants need to visit their doctor during 12-week follow-up period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05571137 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
|
||
| Not yet recruiting |
NCT06243731 -
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
|
||
| Not yet recruiting |
NCT06439342 -
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
|
Phase 3 | |
| Completed |
NCT05576805 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
|
||
| Not yet recruiting |
NCT06213974 -
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
|
||
| Completed |
NCT02775240 -
Study of SHP620 (Maribavir) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01611974 -
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
|
Phase 2 | |
| Completed |
NCT05137717 -
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
|
Phase 3 | |
| Completed |
NCT02931539 -
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
|
Phase 3 | |
| Completed |
NCT02927067 -
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
|
Phase 3 |